D. E. Shaw & Co., Inc. Infla Rx N.V. Call Options Transaction History
D. E. Shaw & Co., Inc.
- $107 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IFRX
# of Institutions
29Shares Held
12.9MCall Options Held
19.3KPut Options Held
0-
Suvretta Capital Management, LLC New York, NY5.73MShares$12.8 Million0.35% of portfolio
-
683 Capital Management, LLC New York, NY2.07MShares$4.64 Million0.29% of portfolio
-
Eversept Partners, LP New York, NY1.62MShares$3.63 Million0.2% of portfolio
-
Ubs Oconnor LLC Chicago, IL798KShares$1.79 Million0.08% of portfolio
-
Ikarian Capital, LLC Dallas, TX705KShares$1.58 Million0.19% of portfolio
About InflaRx N.V.
- Ticker IFRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 44,203,800
- Market Cap $99M
- Description
- InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a nov...